MRG002 — Investigational Agent
Antibody-Drug Conjugate · Phase 2 · Shanghai Miracogen
Mechanism of Action
MRG002 is a HER2-directed antibody-drug conjugate linking an anti-HER2 monoclonal antibody to a monomethyl auristatin E (MMAE) microtubule-inhibitor payload via a cleavable linker. It delivers cytotoxic payload to HER2-expressing cells, including HER2-low tumors.
Investigational Indications
- HER2-low locally advanced or metastatic breast cancer
- HER2-expressing solid tumors